Nuvation Bio (NUVB) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nuvation Bio (NUVB) has outperformed Zenas BioPharma (ZBIO) over the past year, gaining 33.3% versus a gain of 1.3%. Zenas BioPharma is the larger company by market cap ($1.78 billion vs $1.76 billion), about 1.0 times the size, while Nuvation Bio is growing revenue faster (+699.0% vs +100.0%). Nuvation Bio converts more of its revenue into profit, with a net margin of -325.3% versus -3777.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NUVB | ZBIO |
|---|---|---|
| Share price | $5.00 | $27.26 |
| Market cap | $1.76B | $1.78B |
| 1-day change | +1.01% | +3.89% |
| YTD return | -44.20% | -27.73% |
| 1-year return | +33.33% | +1.31% |
| 5-year return | -47.64% | — |
| EPS (TTM) | $-0.44 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $62.90M | $10.00M |
| Revenue growth (YoY) | +698.96% | +100.00% |
| Net income (latest FY) | $-204.63M | $-377.74M |
| Operating margin | -338.72% | -3830.57% |
| Net margin | -325.31% | -3777.37% |
| 52-week high | $9.75 | $44.60 |
| 52-week low | $3.36 | $13.50 |
| Distance from 52-week high | -48.72% | -38.88% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +160.00% | +75.64% |
| Average volume | 5.65M | 733.34K |
| Shares outstanding | 350.12M | 65.18M |
| Employees | 305 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NUVB has outperformed ZBIO by 32.0 percentage points over the past year.
- Nuvation Bio is more profitable, keeping -325.3 cents of every revenue dollar as net income versus -3777.4 cents for Zenas BioPharma.
- Nuvation Bio grew revenue faster in its latest fiscal year (+698.96% vs +100.00%).
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 305 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
NUVB vs ZBIO FAQ
Which is bigger, Nuvation Bio or Zenas BioPharma?
Zenas BioPharma (ZBIO) is larger, with a market capitalization of $1.78B compared with $1.76B for Nuvation Bio (NUVB).
Which stock has performed better over the past year, NUVB or ZBIO?
NUVB returned +33.33% over the past 12 months, compared with +1.31% for ZBIO (price return, excluding dividends). Past performance does not predict future results.
Are Nuvation Bio and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.